Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Natera, Inc. - Common Stock
(NQ:
NTRA
)
206.04
+1.76 (+0.86%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Natera, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
A Look Back at Immuno-Oncology Stocks’ Q1 Earnings: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Pack
June 11, 2025
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers.
Via
StockStory
Topics
Artificial Intelligence
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase
June 10, 2025
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue...
Via
StockStory
9 Health Care Stocks Whale Activity In Today's Session
↗
June 04, 2025
Via
Benzinga
2 Cash-Heavy Stocks for Long-Term Investors and 1 to Be Wary Of
June 02, 2025
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...
Via
StockStory
Earnings Scheduled For May 8, 2025
↗
May 08, 2025
Via
Benzinga
Preview: Natera's Earnings
↗
May 07, 2025
Via
Benzinga
Peering Into Natera's Recent Short Interest
↗
May 02, 2025
Via
Benzinga
3 Mid-Cap Stocks Worth Your Attention
May 27, 2025
Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses...
Via
StockStory
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
↗
May 26, 2025
Via
Benzinga
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
↗
May 12, 2025
Via
Benzinga
8 Analysts Have This To Say About Natera
↗
May 09, 2025
Via
Benzinga
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales
May 08, 2025
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98...
Via
StockStory
How Do Investors Really Feel About Natera?
↗
March 11, 2025
Via
Benzinga
What To Expect From Natera’s (NTRA) Q1 Earnings
May 07, 2025
Genetic testing company Natera (NASDAQ:NTRA). will be reporting earnings tomorrow after market hours. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of
April 29, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...
Via
StockStory
Topics
Stocks
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
↗
April 28, 2025
Via
Benzinga
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 to Turn Down
April 18, 2025
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...
Via
StockStory
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
↗
April 17, 2025
Via
Benzinga
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
↗
April 17, 2025
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Via
Investor's Business Daily
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
April 15, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
April 14, 2025
Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Assessing Natera: Insights From 10 Financial Analysts
↗
April 10, 2025
Via
Benzinga
3 Reasons NTRA Has Explosive Upside Potential
April 08, 2025
Natera currently trades at $141.03 and has been a dream stock for shareholders. It’s returned 351% since April 2020, blowing past the S&P 500’s 87.1% gain. The company has also beaten the index over...
Via
StockStory
Topics
Government
Stocks
27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks
↗
April 07, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
April 07, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst...
Via
StockStory
Topics
Artificial Intelligence
Is the Market Bullish or Bearish on Natera?
↗
April 04, 2025
Via
Benzinga
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
March 20, 2025
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
↗
March 19, 2025
Via
The Motley Fool
1 Mid-Cap Stock to Own for Decades and 2 to Brush Off
March 18, 2025
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...
Via
StockStory
Why Is Natera (NTRA) Stock Soaring Today
March 11, 2025
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 5.2% in the afternoon session after stocks rebounded, following a broad-based sell-off the previous day. The Nasdaq was down 4%, while the...
Via
StockStory
Topics
Stocks
World Trade
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today